Related references
Note: Only part of the references are listed.Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry
T. Buchler et al.
ANNALS OF ONCOLOGY (2012)
A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors
Tianqiang Song et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2011)
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
W. J. Lee et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy
Nilofer S. Azad et al.
CLINICAL CANCER RESEARCH (2009)
Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non-Renal Cell Carcinoma: A Meta-analysis
David Chu et al.
CLINICAL GENITOURINARY CANCER (2009)
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
S. George et al.
EUROPEAN JOURNAL OF CANCER (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib
Adam D. Lipworth et al.
ONCOLOGY (2009)
Risk of hand-foot skin reaction with sorafenibo: A systematic review and metes-analysis
David Chu et al.
ACTA ONCOLOGICA (2008)
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
A. A. M. van der Veldt et al.
BRITISH JOURNAL OF CANCER (2008)
Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome
Antonio Galan Brotons et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
Mario E. Lacouture et al.
ONCOLOGIST (2008)
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy
C-H. Yang et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms
R Erber et al.
FASEB JOURNAL (2003)
Share Paper
